These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21943394)

  • 1. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
    Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
    BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
    Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
    BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
    Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
    BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
    Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
    Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection.
    Ibrahem S; Seth R; O'Sullivan B; Fadhil W; Taniere P; Ilyas M
    Int J Exp Pathol; 2010 Dec; 91(6):500-5. PubMed ID: 21199003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
    Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
    Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
    Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
    Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
    Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
    Lewandowska MA; Jóźwicki W; Żurawski B
    Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
    Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
    Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
    Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
    Shigaki H; Baba Y; Watanabe M; Miyake K; Murata A; Iwagami S; Ishimoto T; Iwatsuki M; Yoshida N; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S485-91. PubMed ID: 23274581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers.
    Magnin S; Viel E; Baraquin A; Valmary-Degano S; Kantelip B; Pretet JL; Mougin C; Bigand M; Girardo B; Borg C; Ferrand C
    J Mol Diagn; 2011 Sep; 13(5):485-92. PubMed ID: 21742054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
    Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
    J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay.
    Jakubauskas A; Griskevicius L
    Arch Pathol Lab Med; 2010 Apr; 134(4):620-4. PubMed ID: 20367313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.